Podcast: Matt Kaeberlein on rapamycin, mTOR and longevity evidence
In this podcast description, Matt Kaeberlein discusses longevity science, separating exciting laboratory findings on rapamycin and mTOR from open questions about benefits in people. [1]
Automatic summary · not editorially reviewed
The key findings
The description says a talk at MIT drew Matt Kaeberlein into aging research, and that he entered the field in 2003. [1]
The description says Kaeberlein distinguishes laboratory findings on rapamycin and mTOR from remaining questions about benefits in people. [1]
The description says the conversation covers biological age tests, the difficulty of defining healthspan and what a trial should measure. [1]
The source at a glance
- Study type / format
- Podcast episode description (video description)
- Population / context
- Not specified; the description concerns aging research and people in general, plus dogs via the Dog Aging Project.
- Summary based on
- Creator description
- Original publication
- September 29, 2026
Kaeberlein's path into aging research
The description says a talk at MIT drew Matt Kaeberlein into aging research, and that he entered the field in 2003. It also links his personal story to the origins of the Dog Aging Project, which the description lists as a resource. These are the creator's framing points; the description gives no further details on the talk or the project's design.
Supporting source [1]
Rapamycin and mTOR: lab findings versus human questions
The description says Kaeberlein walks through rapamycin and mTOR and distinguishes findings that excite him in laboratory research from questions that remain about benefits in people. It also mentions longevity hype and scientific credibility, and his wish for trials of overlooked drugs. The description does not report specific results, doses or human outcomes, so no benefit in people is established here.
Supporting source [1]
Biological clocks, healthspan and trial measurement
The description says the conversation covers biological age tests and the limits of individual test results, the difficulty of defining healthspan, and why a clinical trial needs a clear answer to what will actually be measured. It also lists epigenetic reprogramming as a research wish, without presenting it as an established treatment. These are topics named in the description, not reported study findings.
Supporting source [1]
How to interpret this
Only the video description was available; the video and transcript were not reviewed. The description names topics and the creator's views but reports no study design, sample, results or numbers.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Transcribed · youtube.com · September 29, 2026